High-throughput screening method for protein degradation agent

Through the in vitro screening method of ubiquitin cascade reaction and fluorescein labeling, the problems of high screening cost and high false positive rate of protein degradation agents are solved, and high throughput and low-cost screening of protein degradation agents can be quickly identified with ubiquitous A phosphatically active compound.

CN119023639APending Publication Date: 2024-11-26HANGZHOU INST FOR ADVANCED STUDY UCAS +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411219084.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing protein degrading agent screening methods have problems such as high cost, high experimental instrument requirements, high false positive rates and difficulty in achieving high-throughput screening. In particular, screening methods based on proximity cannot characterize the effects of ubiquitination modification and cellular degradation.

Method used

A multi-component in vitro screening method based on ubiquitin cascade reaction was adopted, and the targets were targeted by using luciferin-labeled ubiquitin and ubiquitin-activated enzymes E1, ubiquitin binding enzymes E2, and ubiquitin ligase E3 under the catalytic action of ATP. The protein is incubated and the fluorescent ubiquitin label modification of the target protein is detected by protein electrophoresis gel imaging, which directly reflects whether the compound has the ability to mediate the ubiquitination of the target protein.

Benefits of technology

It realizes efficient, convenient, cost-effective and efficient screening of protein degradants, can quickly identify compounds with ubiquitination activity, reduce the false positive rate, and is suitable for high-throughput screening of large batches of compounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119023639A_ABST
    Figure CN119023639A_ABST
Patent Text Reader

Abstract

The invention discloses a high-throughput screening method for a protein degradation agent. The high-throughput screening method comprises the following steps: (1) dividing a compound solution to be screened into m rows and n columns; mixing in rows to obtain n row mixed solutions; mixing in rows to obtain a total mixed solution; (2) in the presence of ubiquitin activating enzyme E1, ubiquitin binding enzyme E2, ubiquitin ligase E3 and fluorescein-labeled ubiquitin, incubating the total mixed solution and target protein; (3) after incubation is completed, protein electrophoresis gel imaging detection is carried out; (4) if the total mixed solution contains the degradation agent seedling compound, sequentially judging the belonging column and row of the degradation agent seedling compound according to the steps (2) and (3); and (5) determining the information of the degradation agent seedling compound according to the belonging row and the belonging column. The screening method provided by the invention can directly reflect whether the compound has the capability of mediating ubiquitination of the target protein, and has the characteristics of low requirements on experimental instruments, convenience, rapidness, economy and high efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a high-throughput screening method for protein degradation agents. Background Art

[0002] Targeted protein degradation (TPD) is a technology that achieves targeted degradation of target proteins by mobilizing the inherent ubiquitin-proteasome system (UPS) or lysosomal degradation pathways in cells. Compared with traditional small molecule drugs, TPD has attracted widespread attention because it can target non-drugable proteins that are difficult to target with traditional small molecules, and can directly downregulate the content of target proteins in cells, which is expected to overcome the drug resistance problems that often occur with traditional inhibitors. In this field, the two most studied are proteasome-targeted chimeras (PROTAC) and molecular glue degraders (MGD). PROTAC molecules are heterobifunctional molecules composed of E3 ubiquitin ligase ligands, target protein ligands, and Linkers that connect the two. In vivo, the E3 ubiquitin ligase ligand of the PROTAC molecule binds to the substrate receptor protein of the E3 ubiquitin ligase in the cell, and the target protein ligand binds to the target protein. The linker connecting the two ligands brings the target protein and the E3 ubiquitin ligase closer, and then the target protein is degraded by the UPS system or lysosomal degradation pathway. Molecular glue degraders do not require protein ligands, but instead recruit the target protein to the E3 ubiquitin ligase by inducing a new interaction between the E3 ubiquitin ligase substrate receptor protein and the target protein, and then achieve degradation of the target protein through the UPS system or lysosomal degradation pathway. Whether it is a PROTAC molecule or a molecular glue degrader, both of them bring the target protein and the E3 ubiquitin ligase, which originally have no interaction or weak interaction, closer, and then the target protein is marked with ubiquitin protein and recognized and degraded by the proteasome or lysosomal degradation pathway.

[0003] At present, there is a lack of experience in the design and synthesis of molecular glue degraders, and the discovery of existing molecular glues mostly relies on accidental discoveries. The synthesis of PROTAC molecules is traceable and is no longer the rate-limiting step in the development of PROTAC drugs. In terms of E3 ligase receptor protein ligands, the E3 ligase substrate receptor proteins currently reported to be applied to PROTAC are mainly CRBN, VHL, cIAP and MDM2, among which CRBN and VHL are the most widely used. For the above commonly used E3 receptor proteins, there are mature ligands. It is particularly noteworthy that the degraders currently entering the clinic all use CRBN ligands. Therefore, the present invention specifically develops a screening method for protein degraders targeting CRBN ligands. The target protein ligand often uses the corresponding small molecule inhibitor or agonist. Linker has a larger selection range, usually using alkyl chains and PEG chains of different lengths. The choice of Linker will affect the physical properties of PROTAC and is often the focus of investigation during PROTAC optimization. In addition, the use of computational tools has also greatly contributed to the synthesis and construction of the degrader library. Therefore, for large-scale synthesized degrader molecules, high-throughput screening methods have also become an indispensable part of the degrader drug development process.

[0004] Currently, the methods used for screening or validating degraders can be divided into three categories: one is the cell-free biological screening method; one is the cell-based screening method; and the third is the computer-assisted prediction method.

[0005] Cell-free biological screening methods include fluorescence polarization (FP) for detecting the ability of compounds to bind to E3 ubiquitin ligases or target proteins. FP requires a large amount of protein and is not suitable for high-throughput screening. Screening methods for discovering potential degraders by detecting protein-protein interactions between E3 ubiquitin ligase substrate receptors and target proteins induced by degraders include isothermal titration calorimetry (ITC), amplified luminescence proximity homogeneous assay (ALPHA), time-resolved fluorescent resonance energy transfer (TR-FRET), surface plasmon resonance (SPR) and bio-layer interferometry (BLI). ITC is considered the "gold standard" for identifying binding, but this method requires a large amount of samples, is time-consuming, and has poor experimental reproducibility, which means it is usually not used for high-throughput screening. ALPHA and TR-FRET are both close-range technologies. ALPHA involves multiple incubation processes, and the donor beads are coupled to photosensitive groups, so special attention should be paid during operation. FRET uses long-lived fluorescent groups and does not require light protection during operation, but the microbeads required in both methods are expensive, and the cost of high-throughput screening is high. SPR and BLI both detect binding through spectral methods and display binding kinetics in real time through sensors. However, regardless of SPR or BLI, the sensitivity of detecting small molecules is always a problem, and both require a large amount of protein. In addition, this type of screening method that detects binding has a high false positive rate. Gel filtration chromatography (SEC), co-immunoprecipitation (Co-IP), and mass spectrometry (MS) can also be used for screening and confirmation of degraders, but all three require a high amount of protein. The above technologies are usually not used in high-throughput screening of degraders due to problems such as large protein consumption, high experimental costs and certain limitations on experimental instruments.

[0006] The second major category of cell-based detection methods mainly includes Nano-BRET (NanoLuc Bioluminescence resonance energy transfer) and NanoBiT (NanoLuc Binary Technology) technologies, which can detect protein interactions in real time in living cells. Compared with cell-free detection methods, both do not require protein expression and purification, but require the construction of fusion protein expression and cell transfection; and the detection is carried out in cells, and the results are more reliable based on physiological conditions. However, the cost of this type of screening method is generally high.

[0007] The third type of screening method is based on computer-assisted screening, which mainly simulates the interaction between the target and the candidate degrader through molecular docking software. It is currently mostly used before biological screening experiments to reduce the number of experimental screening compounds.

[0008] In general, in the screening and confirmation of degraders, it is usually necessary to rely on classical experimental technical principles and reasonably design corresponding screening schemes. However, the current screening schemes have certain limitations in terms of experimental costs or operations. The screening method based on proximity can only indicate that the compound has the effect of bringing the target protein and the E3 substrate receptor protein closer, and cannot characterize whether there is ubiquitination modification and cellular degradation effect, and there is a possibility of false positives. Cell-based screening methods are expensive and difficult to achieve high throughput. Computer-assisted screening can only be used as a reference and cannot completely replace experimental screening. Summary of the invention

[0009] The present invention provides a high-throughput screening method for protein degraders, which can directly reflect whether a compound has the ability to mediate ubiquitination of a target protein, and has the characteristics of low requirements for experimental instruments, convenience, speed, economy and high efficiency.

[0010] The technical solution of the present invention is as follows:

[0011] A high-throughput screening method for protein degraders, comprising:

[0012] (1) dividing m×n solutions of compounds to be screened into m rows and n columns; mixing by rows, merging the solutions of the same column in each row into one row, and obtaining n row mixed solutions containing m compounds; mixing by columns, merging n row mixed solutions into one total mixed solution containing m×n compounds;

[0013] (2) incubating the total mixed solution with the target protein in the presence of ubiquitin activating enzyme E1, ubiquitin conjugating enzyme E2, ubiquitin ligase E3, and fluorescein-labeled ubiquitin;

[0014] (3) After the incubation is completed, the ubiquitin modification of the target protein by fluorescent ubiquitin labeling under the action of the total mixed solution is detected by protein electrophoresis gel imaging;

[0015] (4) Based on the results of protein electrophoresis gel imaging, determine whether the total mixed solution contains a degrader lead compound that can mediate ubiquitin modification of the target protein;

[0016] If the total mixed solution contains a degrader hit compound that can mediate ubiquitin modification of the target protein, then:

[0017] (4-1) replacing the total mixed solution with n row mixed solutions respectively, and performing steps (2) and (3) to determine the column to which the degradation agent lead compound belongs;

[0018] (4-2) replacing the total mixed solution with the m compounds in the corresponding columns, and performing steps (2) and (3) to determine the row to which the degradation agent lead compound belongs;

[0019] (5) Determine information of the degradation agent lead compound according to the row and column to which the degradation agent lead compound belongs.

[0020] Preferably, the concentration of the solution of the compound to be screened is 1-10 mmoL / L.

[0021] Preferably, m is 2 to 20; n is 2 to 10. In this technical solution, the hit compound in the mixed system has good activity in mediating target protein ubiquitination, which ensures the screening accuracy while ensuring the screening flux.

[0022] More preferably, the number of the compound solutions to be screened is 10-200; more preferably, 40-160.

[0023] In step (2), the ubiquitin activating enzyme E1, the ubiquitin conjugating enzyme E2, the ubiquitin ligase E3, the fluorescein-labeled ubiquitin and the target protein are full-length or truncated proteins expressed by eukaryotic cells or prokaryotic cells.

[0024] Preferably, step (2) comprises: adding 10× reaction buffer, ubiquitin activating enzyme E1, ubiquitin conjugating enzyme E2, ubiquitin ligase E3, fluorescein-labeled ubiquitin, target protein, and the mixed solution obtained in step (1) into a PCR reaction tube, and finally adding ATP to start the reaction, and incubating at 25-37°C.

[0025] Preferably, the components of the 10× reaction buffer include at least one of 4-hydroxyethyloxazineethanesulfonic acid buffer (HEPES), tris(hydroxymethylaminomethane) hydrochloric acid (Tris-HCl), citric acid / sodium citrate solution, 2-morpholineethanesulfonic acid buffer (MES), and 3-morpholinepropanesulfonic acid buffer (MOPS); more preferably, 4-hydroxyethyloxazineethanesulfonic acid buffer.

[0026] Further preferably, the incubation system also includes sodium chloride, DTT, TCEP, etc.

[0027] Preferably, the incubation system comprises: 20 mmoL / L 4-hydroxyethylazineethanesulfonic acid buffer with a pH of 7.0, 200 mmoL / L NaCl solution, 5 mmoL / L MgCl 2 Solution.

[0028] Preferably, in the incubation system, the concentration of ubiquitin activating enzyme E1 is 0.25-10 μmoL / L, the concentration of ubiquitin conjugating enzyme E2 is 0.25-10 μmoL / L, the concentration of ubiquitin ligase E3 is 0.25-10 μmoL / L, the concentration of fluorescein-labeled ubiquitin is 5-50 μmoL / L, the concentration of target protein is 0.5-10 μmoL / L, and the working concentration of ATP is 1-20 mmoL / L.

[0029] Most preferably, in the incubation system, the concentration of ubiquitin activating enzyme E1 is 0.5 μmoL / L, the concentration of ubiquitin conjugating enzyme E2 is 0.5 μmoL / L, the concentration of ubiquitin ligase E3 is 1 μmoL / L, the concentration of fluorescein-labeled ubiquitin is 20 μmoL / L, the concentration of target protein is 5 μmoL / L, and the working concentration of ATP is 10mmoL / L.

[0030] Preferably, the ubiquitin activating enzyme E1 is UBA1 (Uniprot ID No.: P22314), the ubiquitin conjugating enzyme E2 is UB2D1 (UniProt ID No.: P51668), and the ubiquitin ligase E3 is CRBN (UniProt ID No.: Q96SW2), DDB1 (UniProt ID No.: Q16531), Cul4A (UniProt ID No.: Q13619) and CRL4 composed of RBX1 (UniProt ID No.: P62877) CRBN Complex.

[0031] Preferably, the fluorescein tag carried by ubiquitin includes at least one of fluorescein-5-maleimide (5-FM), rhodamine and CY-5.5 (Sulfo-Cyanine5.5); further preferably, the fluorescein tag carried by ubiquitin is fluorescein-5-maleimide.

[0032] The present invention is an in vitro screening method involving multi-component proteins based on ubiquitin cascade reaction, and the application of fluorescein-labeled ubiquitin can improve the sensitivity of subsequent detection. The ubiquitin activating enzyme E1, ubiquitin conjugating enzyme E2, ubiquitin ligase E3, target protein, fluorescein-labeled ubiquitin and candidate degradation agent molecules required for the ubiquitin cascade reaction are added to the reaction system. Under the catalytic action of ATP, the fluorescein-labeled ubiquitin is transferred to the target protein under the cascade catalysis of E1, E2 and E3, and the product after the reaction is subjected to gel electrophoresis to separate the various protein components. After the gel is subjected to fluorescence imaging and Coomassie brilliant blue staining imaging respectively, the lane is analyzed for the presence of substrate-ubiquitin fluorescence and Coomassie brilliant blue staining bands. If the corresponding bands exist, it means that the degradation agent "lead compound" exists in the compound mixture corresponding to the lane, and the position of the "lead compound" can be traced back.

[0033] Compared with the prior art, the present invention has the following beneficial effects:

[0034] The present invention uses fluorescently labeled ubiquitin and an in vitro ubiquitination reaction system to establish a high-throughput screening method for protein degraders, and provides a method for efficiently screening "lead compounds" of degraders from mixed compounds. The screening method proposed in the present invention is characterized by high efficiency, convenience, low economic cost, and low technical threshold for experimental operation.

[0035] In addition, the screening method of the present invention directly reflects the ability of the compound to ubiquitinate the substrate protein in vitro. The method can exclude false positive hit compounds that only bring the distance between E3 and the target protein closer but do not ubiquitinate the target protein. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Schematic diagram of the principle of high-throughput screening method for protein degraders based on substrate ubiquitination modification.

[0037] Figure 2 This is a schematic diagram of the operation flow of mixing 160 compounds in the “two-step method” in the example.

[0038] Figure 3 Schematic diagram of the process for determining the position information of hit compounds in the high-throughput screening method for degraders.

[0039] Figure 4This is the fluorescence imaging and Coomassie Brilliant Blue staining imaging of Example 1.

[0040] Figure 5 This is the fluorescence imaging and Coomassie Brilliant Blue staining imaging of Example 2.

[0041] Figure 6 This is the fluorescence imaging and Coomassie Brilliant Blue staining imaging of Example 3.

[0042] Figure 7 Results of high-throughput screening of compounds targeting BRD4 (BD1), (a) is a 160-in-1 mixture, (b) is 10 mixtures obtained after merging by row, and (c) is the 16 compounds in column 5.

[0043] Figure 8 Results of high-throughput screening of compounds targeting BPTF, (a) is an 80-in-1 mixture, (b) is 10 mixtures obtained after merging by row, and (c) is the 8 compounds in column 4. DETAILED DESCRIPTION

[0044] The present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be pointed out that the embodiments described below are intended to facilitate the understanding of the present invention and do not have any limiting effect on the present invention.

[0045] like Figure 1 As shown, the high-throughput screening method of protein degradation agents based on substrate ubiquitination modification of the present invention comprises:

[0046] (1) mixing the compounds to be screened by a specific scheme;

[0047] (2) incubating the compound mixture with the target protein in the presence of ubiquitin activating enzyme E1, ubiquitin conjugating enzyme E2, ubiquitin ligase E3, and fluorescein-labeled ubiquitin;

[0048] (3) Using an imaging system to detect the fluorescent ubiquitin modification of target proteins under the action of different compound mixtures;

[0049] (4) Based on the imaging test results, the location of the “lead compound” of the degradation agent is traced back and the information is confirmed.

[0050] like Figure 2 As shown, the step of mixing the compounds to be screened includes:

[0051] The 160 compound stock solutions were stored in two 96-well plates, each well containing one compound at a concentration of 1mM to 10mM, 10 compounds per row, and 16 rows. The mixture was mixed in the following two steps: first, row-by-row merging, using a multi-channel gun to take a certain volume from the wells in the same column of each row of the multi-well plate and merge into one row, to obtain 10 mixed compounds containing 16 compounds respectively; then, column-by-column merging, mixing the 10 mixed compounds obtained in the previous step. After two mergings, a mixed compound containing 160 compounds was obtained.

[0052] Use an imaging instrument with fluorescence imaging and conventional codon-stained gel imaging functions to perform fluorescence and codon-stained color development. Analyze whether there are fluorescent and codon-stained bands of the substrate protein ~ ubiquitin in the lane. If there are corresponding bands, it means that the compound mixture added to the reaction tube corresponding to the lane contains a degrader "lead compound", and the position of the "lead compound" can be traced back.

[0053] like Figure 3 As shown, based on the imaging test results, the location of the “lead compound” of the degradation agent is traced back and the information is confirmed, including the following steps:

[0054] First, determine which mother plate of the original compound the "shoot compound" belongs to. Then, perform step (2) reaction on the 10 mixed compounds containing 16 compounds obtained by merging the plates. Determine the column number to which the "shoot compound" belongs based on the results. Then, perform step (2) reaction on the 16 compounds in the column. Determine the row number to which the "shoot compound" belongs based on the results. This determines which row of the original mother plate the "shoot compound" belongs to. After this step, we can determine the position of the "shoot compound" in the original compound plate.

[0055] The information of the lead compound is determined according to the electronic file of the original compound master plate, wherein the electronic file of the original compound master plate is the position of each compound in the storage container and the corresponding compound information recorded when the compound library is established.

[0056] In the following examples, the ubiquitin activating enzyme E1 is UBA1 (UniProt ID No.: P22314), the ubiquitin conjugating enzyme E2 is UB2D1 (UniProt ID No.: P51668), and the ubiquitin ligase E3 is CRL4 composed of CRBN (UniProt ID No.: Q96SW2), DDB1 (UniProt ID No.: Q16531), Cul4A (UniProt ID No.: Q13619) and RBX1 (UniProt ID No.: P62877). CRBN Complex.

[0057] Embodiment 1:

[0058] The effect of the positive compound dBET23 on the in vitro ubiquitination of the target protein BRD4 (BD1) was tested at different reaction times.

[0059] dBET23 is a reported efficient and specific degradation agent targeting CRBN and BRD4 (BD1) proteins. In this example, the compound was selected to perform tests with different reaction times (0, 0.5, 1, 2, 3, 5 h) according to the experimental method of the present invention to confirm the feasibility of the experimental method of the present invention.

[0060] Using a high-throughput screening method for protein degraders based on substrate ubiquitination modification, the effect of dBET23-mediated ubiquitination of the target protein BRD4 (BD1) was detected at different reaction times. By comparing the bands of the target protein BD1-ubiquitin at different times, the effect of reaction time on the screening system was analyzed.

[0061] (1) Material preparation:

[0062] E1 protein, E2 protein, E3 protein, GST-BRD4 (BD1) (UniProt ID No.: O60885, aa 49-170) protein, fluorescently labeled ubiquitin, ATP (100 mM aqueous solution, Bio-Industry, A600311), 10× reaction buffer (200 mM HEPES, pH 7.0, 2 M NaCl, 50 mM MgCl 2 ), protein buffer (20mM HEPES, pH 7.0, 200mM NaCl, 3mM TCEP), positive compound dBET23 (MCE, 10mM), 160 compounds (laboratory compound library), desktop centrifuge (DLAB), PCR instrument (Bio-Rad), 6×SDS-PAGE protein loading buffer, 4%-20% precast protein gel (GenScript), protein gel electrophoresis instrument (Bio-Rad), imager (Azure Imager 600).

[0063] (2) Operation steps:

[0064] ① Take two 96-well plates each containing 80 compounds (the mother solution concentration of each compound is 10mM, dissolved in DMSO). First, merge by row, use a 10-channel pipette to take 1μL of compound from each well in each row of the two plates, merge into one row, and mix thoroughly. During this process, replace any well with the positive compound dBET23. At this time, there are 16 compounds in each merged well. Then, merge by column, take 2μL from each well in each column of the compound obtained in the previous step, and merge into one column. At this point, after two merges, a mixture containing 160 compounds is obtained, and the positive compound dBET23 is included. After merging, the concentration of each compound is 62.5μM and the DMSO concentration is 100%.

[0065] ② Use protein buffer to dilute E1, E2, E3, GST-BRD4 (BD1) protein and fluorescently labeled ubiquitin to 5μM, 5μM, 10μM, 50μM and 200μM respectively. Experimental groups with reaction time of 0.5h, 1h, 2h, 3h and 5h were set up, and a control group with reaction time of 0 was set up. Each group was mixed with 1μL E1, E2, E3, GST-BRD4 (BD1) protein, fluorescently labeled ubiquitin, 10× reaction buffer, 0.5μL mixed compound and 2.5μL protein buffer. Finally, 1μL ATP was added and the reaction was carried out at 37℃. The total reaction system was 10μL. After different reaction times, 2μL 6×SDS-PAGE protein loading buffer was added to the corresponding tube reaction solution to terminate the reaction. After the reaction, protein gel electrophoresis was performed. After the electrophoresis, fluorescence imaging and staining imaging were performed using an imager.

[0066] (3) Experimental results analysis:

[0067] like Figure 4 As shown, in the control group with a reaction time of 0 min, no BD1-Ub band was found. As the reaction time increases, the BD1-Ub band becomes more and more obvious, and the BD1-Ub and BD1-2Ub bands can be clearly distinguished. Among them, the BD1-Ub bands are similar in the experimental groups with a reaction time of 3 h and 5 h. Therefore, in order to achieve high sensitivity and easy-to-distinguish results while reducing the probability of false positives, it is recommended to use a 3 h reaction time for the remaining screening experiments. In addition, this example confirms the sensitivity and feasibility of the method.

[0068] Embodiment 2:

[0069] The effects of different concentrations of the positive compound dBET23 on the in vitro ubiquitination of the target protein BRD4 (BD1) were tested.

[0070] Using a high-throughput screening method for protein degraders based on substrate ubiquitination modification, different concentrations of dBET23 were used to detect its effect on mediating ubiquitination of the target protein BRD4 (BD1). By comparing the bands of target protein BD1~Ub in experimental groups with different concentrations, the effect of compound concentration on the screening system was analyzed.

[0071] (1) Material preparation:

[0072] E1 protein, E2 protein, E3 protein, GST-BRD4 (BD1) (UniProt ID No.: O60885, aa 49-170) protein, fluorescently labeled ubiquitin, ATP (100 mM aqueous solution, Bio-Industry, A600311), 10× reaction buffer (200 mM HEPES, pH 7.0, 2 M NaCl, 50 mM MgCl 2 ), protein buffer (20mM HEPES, pH 7.0, 200mM NaCl, 3mM TCEP), positive compound dBET23 (MCE, 10mM), 160 compounds (laboratory compound library), desktop centrifuge (DLAB), PCR instrument (Bio-Rad), 6×SDS-PAGE protein loading buffer, 4%-20% precast protein gel (GenScript), protein gel electrophoresis instrument (Bio-Rad), imager (Azure Imager 600).

[0073] (2) Operation steps:

[0074] ① Take two 96-well plates each containing 80 compounds (the mother solution concentration of each compound is 10mM, dissolved in DMSO). First, merge by rows, use a 10-channel pipette to take 1μL of compound from each well in each row of the two plates, merge into one row, and mix thoroughly. At this point, there are 16 compounds in each merged well. Then, merge by columns, take 2μL from each well in each column of the compounds obtained in the previous step, and merge into one column. At this point, after two merges, a mixture of 160 compounds is obtained. After merging, the concentration of each compound is 62.5μM and the DMSO concentration is 100%.

[0075] ② Dissolve dBET23 to 10 mM in DMSO, and then dilute it to 500 μM (5% DMSO) with protein buffer. Then, dilute 500 μM dBET23 in 5% DMSO in a two-fold gradient to obtain 500 μM, 250 μM, 125 μM, 62.5 μM, 31.25 μM, 15.6 μM, 7.8 μM, and 3.9 μM dBET23 stock solutions containing 5% DMSO.

[0076] ③ Use protein buffer to dilute E1, E2, E3, GST-BRD4 (BD1) protein, and fluorescently labeled ubiquitin to 5μM, 5μM, 10μM, 50μM, and 200μM, respectively. Each group was mixed with 1μL E1, E2, E3, GST-BRD4 (BD1) protein, fluorescently labeled ubiquitin, 10× reaction buffer, 0.5μL of the compound mixed in step ①, 1μL of different concentrations of dBET23 in step ②, and 1.5μL protein buffer. Finally, 1μL ATP was added and reacted at 37℃ for 3h. The total reaction system was 10μL. In addition to the above experimental groups, two control groups were set up in this experiment. One group replaced the positive compound dBET23 with 5% DMSO, which was equivalent to the absence of positive compounds in this group. The other control group selected the highest concentration of dBET23, that is, 1μL 500μM dBET was added, and the reaction time was 0min. After the reaction is completed, 2 μL of 6×SDS-PAGE protein loading buffer is added to the reaction solution to terminate the reaction. Samples are taken for protein gel electrophoresis. After the electrophoresis is completed, fluorescence imaging and staining imaging are performed using an imaging device.

[0077] (3) Experimental results analysis:

[0078] like Figure 5 As shown, in the control group with a reaction time of 0 min, no BD1-Ub bands were seen. In the control group without dBET23, faint BD1-Ub bands were seen, indicating that as the reaction time increases, non-specific substrates and ubiquitin may bind. In the experimental group, as the concentration of the positive compound dBET23 increases, the BD1-Ub bands become more obvious. At the lowest working concentration of 390 nM, the BD1-Ub bands are also more obvious than those in the control group. This shows that the screening method of the present invention has high sensitivity and is suitable for screening compounds of different concentrations, suggesting that the screening system can be used for compounds with different activities.

[0079] Embodiment 3:

[0080] Testing the effects of different mixing systems on screening results

[0081] CPS2 is the first reported efficient, selective, and irreversible PROTAC degrader targeting CRBN and CDK2. This example uses a high-throughput screening method for protein degraders based on substrate ubiquitination modification, using two mixed systems of 80 mixed 1 and 160 mixed 1, respectively, to detect the effect of positive compound CPS2 on target protein CDK2 ubiquitination, and by comparing the bands of target protein CDK2~Ub in the two mixed systems, analyze the effects of different mixing methods on the screening system.

[0082] (1) Material preparation:

[0083] E1 protein, E2 protein, E3 protein, CDK2 (UniProt ID No.: P24941) protein, fluorescently labeled ubiquitin, ATP (100 mM aqueous solution, Bio-Industry, A600311), 10× reaction buffer (200 mM HEPES, pH 7.0, 2 M NaCl, 50 mM MgCl 2 ), protein buffer (20mM HEPES, pH 7.0, 200mM NaCl, 3mM TCEP), positive compound CPS2 (MCE, 10mM), 800 compounds (laboratory compound library), desktop centrifuge (DLAB), PCR instrument (Bio-Rad), 6×SDS-PAGE protein loading buffer, 4%-20% precast protein gel (GenScript), protein gel electrophoresis instrument (Bio-Rad), imager (AzureImager 600).

[0084] (2) Operation steps:

[0085] ① Take two 96-well plates each containing 80 compounds (the mother solution concentration of each compound is 10mM, dissolved in DMSO). First, merge by row, use a 10-channel pipette to take 1μL of compound from each well in each row of the two plates, merge into one row, and mix thoroughly. At this time, there are 16 compounds in each merged well. Then, merge by column, take 2μL from each well in each column of the compound obtained in the previous step, and merge into one column. At this time, after two mergers, a group of mixtures containing 160 compounds is obtained. After merging, the concentration of each compound is 62.5μM, and the DMSO concentration is 100%. By a similar method, only one 96-well plate containing 80 compounds is merged by row and then by column to obtain a group of mixtures containing 80 compounds, in which the concentration of each compound is 125μM and the DMSO concentration is 100%. In this embodiment, 5 groups of 160 mixed 1 and 80 mixed 1 mixtures are prepared respectively. Furthermore, before mixing, two groups were randomly selected, and the compound in one of the wells was replaced with the positive compound CPS2 for merging.

[0086] ② Use protein buffer to dilute E1, E2, E3, CDK2 protein, and fluorescently labeled ubiquitin to 5μM, 5μM, 10μM, 50μM, and 200μM, respectively. Mix 1μL of E1, E2, E3, CDK2 protein, fluorescently labeled ubiquitin, 10× reaction buffer, 0.5μL of the compound mixed in step ①, and 2.5μL of protein buffer in each group. Finally, add 1μL ATP, the total reaction system is 10μL, and react at 37℃ for 3h. After the reaction is completed, add 2μL 6×SDS-PAGE protein loading buffer to the reaction solution to terminate the reaction. Take samples for protein gel electrophoresis. After the electrophoresis, use an imager to perform fluorescence imaging and staining imaging respectively.

[0087] (3) Experimental results analysis:

[0088] like Figure 6 As shown, in the component without adding positive compound, CDK2-Ub band was not found. In the experimental group containing positive compound CPS2, CDK2-Ub band was visible, indicating that the method of improving screening throughput by mixing different numbers of compounds into one group for experimental analysis in the present invention is feasible. In addition, in the 80-mixed-1 system, since the working concentration of the positive compound is twice that of the 160-mixed-1 system, the substrate-ubiquitin band in the 80-mixed-1 system is slightly more obvious than that in the 160-mixed-1 system, suggesting that for compounds with low activity or uncertain activity, the 80-mixed-1 or 40-mixed-1 screening system can be selected for initial screening to improve the positive rate.

[0089] Embodiment 4:

[0090] High-throughput screening and validation of compounds targeting BRD4 (BD1)

[0091] The present invention provides a method for improving screening throughput by orderly mixing compounds stored in a well plate. First, the mixture is used for screening, and the mixture containing active compounds is expanded to trace back the position information of the active compounds. In this embodiment, the target BRD4 (BD1) is taken as an example. In a well plate containing 160 compounds, one well is randomly replaced with a positive compound dBET23. The screening and information tracing process of active compounds is simulated.

[0092] (1) Material preparation:

[0093] E1 protein, E2 protein, E3 protein, GST-BRD4 (BD1) (UniProt ID No.: O60885, aa 49-170), fluorescently labeled ubiquitin, ATP (100 mM aqueous solution, Bio-Industry, A600311), 10× reaction buffer (200 mM HEPES, pH 7.0, 2 M NaCl, 50 mM MgCl 2 ), protein buffer (20mM HEPES, pH 7.0, 200mM NaCl, 3mM TCEP), positive compound dBET23 (MCE, 10mM), 160 compounds (laboratory compound library), desktop centrifuge (DLAB), PCR instrument (Bio-Rad), 6×SDS-PAGE protein loading buffer, 4%-20% precast protein gel (GenScript), protein gel electrophoresis instrument (Bio-Rad), imager (Azure Imager 600).

[0094] (2) Operation steps:

[0095] i. Screening of mixtures

[0096] ① Take two 96-well plates each containing 80 compounds (the mother solution concentration of each compound is 10mM, dissolved in DMSO), and replace the compound in any well with compound dBET23. First, merge by row, use a 10-channel pipette to take 1μL of compound from each well in each row of the two plates, merge into one row, and mix thoroughly. At this point, there are 16 compounds in each merged well. Then, merge by column, take 2μL from each well in each column of the compound obtained in the previous step, and merge into one column. At this point, after two merges, a mixture of 160 compounds is obtained. After merging, the concentration of each compound is 62.5μM and the DMSO concentration is 100%.

[0097] ② Use protein buffer to dilute E1, E2, E3, GST-BRD4 (BD1), and fluorescently labeled ubiquitin to 5μM, 5μM, 10μM, 50μM, and 200μM, respectively. Mix 1μL of E1, E2, E3, BD1 protein, fluorescently labeled ubiquitin, 10× reaction buffer, 0.5μL of the compound mixed in step ①, and 2.5μL of protein buffer in each group. Finally, add 1μL ATP, the total reaction system is 10μL, and react at 37℃ for 3h. After the reaction is completed, add 2μL 6×SDS-PAGE protein loading buffer to the reaction solution to terminate the reaction. Take samples for protein gel electrophoresis. After the electrophoresis, use an imager to perform fluorescence imaging and staining imaging respectively.

[0098] ③Result analysis: Analyze the fluorescence color image and Coomassie brilliant blue staining image of protein gel ( Figure 7 In (a), clear BD1-Ub bands can be seen in the lane containing the positive compound, indicating that the positive compound still has the activity of mediating BD1 ubiquitination in the 160:1 mixed system.

[0099] ii. Go back to the column where the “prospect compound” is located

[0100] Repeat step ② for the 10 mixture components obtained by merging rows in step ①. Analysis of the protein gel image shows that the BD1-ubiquitin band appears in the lane where the mixture in column 5 is added ( Figure 7 (b)), thereby indicating that the column where the active compound is located is "column 5".

[0101] iii. Go back to the line where the “lead compound” is located

[0102] Repeat step ② for the 16 compounds in row 5. Analysis of the protein gel shows that a BD1-ubiquitin band appears in the lane with the compound in row G ( Figure 7(c)), indicating that the row where the active compound is located is row "G". Through two-step backtracking, we can finally determine that the well plate position where the positive compound dBET23 is located is "G5" of the first plate.

[0103] (3) Experimental results analysis:

[0104] This example uses the positive compound dBET23 of BD1 as a tool to simulate the process of orderly mixing, screening and gradual expansion of the compounds in the present invention to finally obtain the information of active compounds, and proves the feasibility of this method. In the specific screening process, different specifications of compound mixing methods can be selected according to the judgment of compound activity to achieve better screening results.

[0105] Embodiment 5:

[0106] High-throughput screening of targeted BPTF degraders

[0107] BPTF (bromodomain PHD finger transcription factor) is a protein containing a BRD domain. It plays a key role in regulating the expression of downstream related genes through specific recognition of histone lysine acetylation. Dysfunction of BPTF is closely related to the occurrence and development of many human diseases, especially cancer. Therefore, BPTFBRD is an important epigenetic drug target for the treatment of cancer. The method described in the present invention is used to screen "lead compounds" of degraders targeting CRBN and BPTF BRD.

[0108] (1) Material preparation:

[0109] E1 protein, E2 protein, E3 protein, BPTF BRD (UniProt ID No.: Q12830, aa 2914-3037) protein, fluorescently labeled ubiquitin, ATP (100 mM aqueous solution, Bio-Industry, A600311), 10× reaction buffer (200 mM HEPES, pH 7.0, 2 M NaCl, 50 mM MgCl 2 ), protein buffer (20 mM HEPES, pH 7.0, 200 mM NaCl, 3 mM TCEP), 480 compounds (laboratory compound library), desktop centrifuge (DLAB), PCR instrument (Bio-Rad), 6× SDS-PAGE protein loading buffer, 4%-20% precast protein gel (GenScript), protein gel electrophoresis instrument (Bio-Rad), imager (Azure Imager600).

[0110] (2) Operation steps:

[0111] i. Screening of mixtures

[0112] ① Compound mixing: Take 6 96-well plates containing 80 compounds (the mother solution concentration of each compound is 10mM, dissolved in DMSO), and mix the 80 compounds in each plate into a group. First, merge by rows, use a 10-channel pipette to take 1μL of compound from each well in each row of a plate, merge into a row, and mix thoroughly. At this point, there are 8 compounds in each merged well. Then, merge by columns, take 2μL from each well in each column of the compounds obtained in the previous step, and merge into one column. At this point, after two merges, a mixture of 80 compounds is obtained. After merging, the concentration of each compound is 125μM and the DMSO concentration is 100%.

[0113] ② Use protein buffer to dilute E1, E2, E3, BPTF BRD, and fluorescently labeled ubiquitin to 5μM, 5μM, 10μM, 50μM, and 200μM, respectively. Mix 1μL of E1, E2, E3, BPTF BRD protein, fluorescently labeled ubiquitin, 10× reaction buffer, 0.5μL of the compound mixed in step ①, and 2.5μL of protein buffer in each group. Finally, add 1μL ATP, the total reaction system is 10μL, and react at 37℃ for 3h. After the reaction is completed, add 2μL 6×SDS-PAGE protein loading buffer to the reaction solution to terminate the reaction. Take samples for protein gel electrophoresis. After the electrophoresis, use an imager to perform fluorescence imaging and staining imaging respectively.

[0114] ③Result analysis: Analyze the fluorescence color image and Coomassie brilliant blue staining image of protein gel ( Figure 8 In (a), a clear BPTF-ubiquitin band can be seen in a lane, indicating that the compound mixture added to the reaction tube corresponding to the lane contains a "lead compound" of a degrader targeting CRBN and BPTF BRD.

[0115] ii. Go back to the column where the “prospect compound” is located

[0116] First, determine the plate where the "lead compound" is located as plate "2", and then repeat step ② for the 10 mixture components obtained by merging rows according to step ①. Analysis of the protein gel image shows that BPTF-ubiquitin bands appear in the lane where the mixture in column 4 is added ( Figure 8 (b)), thereby indicating that the column where the active compound is located is "column 4".

[0117] iii. Go back to the line where the “lead compound” is located

[0118] Repeat step ② for the 8 compounds in row 4 of the plate. Analysis of the protein gel image shows that a BPTF-ubiquitin band appears in the lane with the compound in row C ( Figure 8(c)), indicating that the row where the active compound is located is row "C". Through two-step backtracking, we can finally determine that the well plate position where the "lead compound" is located is well "C4" of the second plate.

[0119] The information of the lead compound is determined based on the electronic file of the original compound master board. The electronic file of the original compound master board is the location of each compound in the storage container and the corresponding compound information recorded when the compound library was established. The compound information includes but is not limited to the CAS number, structure, molecular formula, and relative molecular mass of each compound.

[0120] The embodiments described above provide a detailed description of the technical solutions and beneficial effects of the present invention. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, supplements and equivalent substitutions made within the scope of the principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A high-throughput screening method for protein degradation agents, characterized in that: include: (1) dividing m×n solutions of compounds to be screened into m rows and n columns; mixing by rows, merging the solutions of the same column in each row into one row, and obtaining n row mixed solutions containing m compounds; mixing by columns, merging n row mixed solutions into one total mixed solution containing m×n compounds; (2) incubating the total mixed solution with the target protein in the presence of ubiquitin activating enzyme E1, ubiquitin conjugating enzyme E2, ubiquitin ligase E3, and fluorescein-labeled ubiquitin; (3) After the incubation is completed, the ubiquitin modification of the target protein by fluorescent ubiquitin labeling under the action of the total mixed solution is detected by protein electrophoresis gel imaging; (4) Based on the results of protein electrophoresis gel imaging, determine whether the total mixed solution contains a degrader lead compound that can mediate ubiquitin modification of the target protein; If the total mixed solution contains a degrader hit compound that can mediate ubiquitin modification of the target protein, then: (4-1) replacing the total mixed solution with n row mixed solutions respectively, and performing steps (2) and (3) to determine the column to which the degradation agent lead compound belongs; (4-2) replacing the total mixed solution with the m compounds in the corresponding columns, and performing steps (2) and (3) to determine the row to which the degradation agent lead compound belongs; (5) Determine information of the degradation agent lead compound according to the row and column to which the degradation agent lead compound belongs.

2. The high-throughput screening method for protein degradation agents according to claim 1, characterized in that: The concentration of the solution of the compound to be screened is 1-10 mmoL / L.

3. The high-throughput screening method for protein degradation agents according to claim 1, characterized in that: m is 2 to 20; n is 2 to 10.

4. The high-throughput screening method for protein degradation agents according to claim 1, characterized in that: Step (2) comprises: adding 10× reaction buffer, ubiquitin activating enzyme E1, ubiquitin conjugating enzyme E2, ubiquitin ligase E3, fluorescein-labeled ubiquitin, target protein, and the mixed solution obtained in step (1) into a PCR reaction tube, and finally adding ATP to start the reaction, and incubating at 25-37° C.

5. The high-throughput screening method for protein degradation agents according to claim 4, characterized in that: The components of the 10× reaction buffer include at least one of 4-hydroxyethyloxazineethanesulfonic acid buffer, tris(hydroxymethylaminomethane)hydrochloric acid, citric acid / sodium citrate solution, 2-morpholineethanesulfonic acid buffer, and 3-morpholinepropanesulfonic acid buffer.

6. The high-throughput screening method for protein degradation agents according to claim 4, characterized in that: The incubation system includes: 20mmoL / L 4-hydroxyethylazineethanesulfonic acid buffer with a pH of 7.0, 200mmoL / L NaCl solution, and 5mmoL / L MgCl2 solution.

7. The high-throughput screening method for protein degradation agents according to claim 1, characterized in that: In the incubation system, the concentration of ubiquitin activating enzyme E1 is 0.25-10 μmoL / L, the concentration of ubiquitin conjugating enzyme E2 is 0.25-10 μmoL / L, the concentration of ubiquitin ligase E3 is 0.25-10 μmoL / L, the concentration of fluorescein-labeled ubiquitin is 5-50 μmoL / L, the concentration of target protein is 0.5-10 μmoL / L, and the working concentration of ATP is 1-20 mmoL / L.

8. The high-throughput screening method for protein degradation agents according to claim 7, characterized in that: In the incubation system, the concentration of ubiquitin activating enzyme E1 was 0.5 μmoL / L, the concentration of ubiquitin conjugating enzyme E2 was 0.5 μmoL / L, the concentration of ubiquitin ligase E3 was 1 μmoL / L, the concentration of fluorescein-labeled ubiquitin was 20 μmoL / L, the concentration of target protein was 5 μmoL / L, and the working concentration of ATP was 10 mmoL / L.

9. The high-throughput screening method for protein degradation agents according to claim 1, characterized in that: The ubiquitin activating enzyme E1 is UBA1, the ubiquitin conjugating enzyme E2 is UB2D1, and the ubiquitin ligase E3 is CRL4 composed of CRBN, DDB1, Cul4A and RBX1. CRBN Complex.

10. The high-throughput screening method for protein degradation agents according to claim 1, characterized in that: The fluorescent tag carried by ubiquitin includes at least one of fluorescein-5-maleimide, rhodamine and CY-5.5.

Citation Information

Cited By

  • Screening method of molecular glue drug and application of molecular glue drug in screening of degradable drugs

    CN121011276A